Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

Shares are listed at Bombay Stock Exchange (BSE), National Stock Exchange (NSE), and Hyderabad Stock Exchange(HSE). It has a state of the art R&D center recognized by Department of Scientific & Industrial Research (DSIR), Ministry of Science and Technology, Government of India. Also, it has world class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Life Science Companies for New Chemical Entities (NCE's).

Business Units

Suven Life Sciences Ltd.

TTK Healthcare Ltd.

RPG Life Sciences Ltd.

Dishman Carbogen Amcis Ltd.

Hester Biosciences Ltd.

Morepen Laboratories Ltd.

Solara Active Pharma Sciences Ltd.

Bajaj Healthcare Ltd.

Orchid Pharma Ltd.

Medicamen Biotech Ltd.

NGLFINE

Themis Medicare Ltd.

Jagsonpal Pharmaceuticals Ltd.

Panacea Biotec Ltd.

Alembic Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	1,392 Cr		EPS	-1.3		High	65.05
Stock P/E	0.0		Net Profit Margin	-528.4		Low	63.3

Market Cap	1,392 Cr	ROE	-49.3%
P/E Ratio(TTM)	0.0	EPS(TTM)	-6.8
P/B Ratio	1.6	Dividend Yield	0.0%
Industry P/E	65.2	Book Value	39.6
		Face Value	1.0

SUVEN